Cyclophilin A – Calcineurin phosphatase complex (CypA-CaN complex)

The Cyclophilin A – Calcineurin phosphatase complex is a critical pharmacological assembly formed when the immunosuppressant drug Cyclosporine A binds to its intracellular receptor, Cyclophilin A (PPIA) [1]. This binary drug-protein complex then associates with Calcineurin, a calcium-calmodulin-dependent serine/threonine phosphatase composed of catalytic (PPP3CA) and regulatory (PPP3R1) subunits [2]. The primary biological function of this interaction is the potent inhibition of Calcineurin's phosphatase activity, which is essential for the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT) [3]. Under normal physiological conditions, dephosphorylated NFAT translocates to the nucleus to induce the transcription of pro-inflammatory cytokines, most notably Interleukin-2 (IL-2), which drives T-cell proliferation and the adaptive immune response [4]. By blocking this pathway, the CypA-CaN complex acts as a cornerstone of modern transplant medicine, preventing the rejection of solid organ allografts and managing autoimmune disorders like psoriasis and rheumatoid arthritis [5]. However, because Calcineurin and Cyclophilin A are ubiquitously expressed, therapeutic modulation of this complex is associated with significant adverse effects, including dose-limiting nephrotoxicity and neurotoxicity [6].

Other names

PPIA-PPP3CA complexCyclosporine-Cyclophilin-Calcineurin complexImmunophilin-phosphatase complexCypA-CaN complex

The drug (e.g., Cyclosporine) binds to Cyclophilin A to form a gain-of-function complex that competitively inhibits the phosphatase activity of Calcineurin, preventing the dephosphorylation and nuclear translocation of NFAT.